Tacrolimus Ointment 0.1%

FDA Drug Profile — Tacrolimus

Tacrolimus Ointment 0.1% is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including Tacrolimus. Available dosage form: ointment.

Drug details

Generic Name
Tacrolimus Ointment 0.1%
Brand Names
Tacrolimus
Application Number
ANDA212387
Sponsor
Encube Ethicals, Inc.
NDC Codes
1
Dosage Forms
OINTMENT
Routes
TOPICAL
Active Ingredients
TACROLIMUS

Indications and Usage

INDICATIONS AND USAGE Tacrolimus ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. Tacrolimus ointment is not indicated for children younger than 2 years of age (see boxed WARNING , WARNINGS and PRECAUTIONS : Pediatric Use ).

Warnings

Prolonged systemic use of calcineurin inhibitors for sustained immunosuppression in animal studies and transplant patients following systemic administration has been associated with an increased risk of infections, lymphomas, and skin malignancies. These risks are associated with the intensity and duration of immunosuppression. Based on the information above and the mechanism of action, there is a concern about potential risk with the use of topical calcineurin inhibitors, including tacrolimus ointment. While a causal relationship has not been established, rare cases of skin malignancy and lymphoma have been reported in patients treated with topical calcineurin inhibitors, including tacrolimus ointment. Therefore: Tacrolimus ointment should not be used in immunocompromised adults and children. If signs and symptoms of atopic dermatitis do not improve within 6 weeks, patients should be re- examined by their healthcare provider and their diagnosis be confirmed (see PRECAUTIONS : General ). The safety of tacrolimus ointment has not been established beyond one year of non-continuous use. (See CLINICAL PHARMACOLOGY , boxed WARNING , INDICATIONS AND USAGE , and DOSAGE AND ADMINISTRATION ).

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.